Human pancreatic pluripotential stem cell line

• US 20030003088A1
• Filed: 04/30/2002
• Published: 01/02/2003
• Est. Priority Date: 05/03/2001
• Status: Abandoned Application

• Current Assignee: Board of Trustee Operating Michigan State University, University Health Network
• Original Assignee: The Board of Trustees of Michigan State University (Michigan State University)
• Inventors: VanCamp, Loretta, Olson, Lawrence K., Tsao, Ming Sound, Trosko, James E., Madhukar, Burra V.
• Application Number:
  US10/135,801
• Publication Number:
  US 20030003088A1
• Time in Patent Office: Days
• US Class Current: 424/93.21
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C12N 2501/01 Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
• CPC Class Codes: C12N 2510/02 Cells for production
• CPC Class Codes: C12N 2510/04 Immortalised cells
• CPC Class Codes: C12N 2710/20022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2710/22022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2740/10043 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 5/0676 Pancreatic cells

Abstract

A human pancreatic ductal epithelial cell line immortalized with the human papilloma virus E6 and E7 genes which has stem cell-like characteristics and which can be induced to differentiate into ductal-like cells and beta-like cells that produce insulin. The immortal cells or derivative thereof are useful for treating insulin-dependent diabetes and in assays for determining the ability of a chemical to induce pancreatic stem cell differentiation or malignancy.

Claims

1. A human pancreatic ductal cell line immortalized with human papilloma virus genes E6 and E7 and which is capable of producing insulin, wherein the cells are gap junctional intercellular communication competent and are capable of expressing connexin43 gap junction protein upon induction by agents stimulating the production of cyclic AMP.

3. The cell line of claim 1, wherein the human papilloma virus genes E6 and E7 are provided by a retrovirus.

4. The cell line of claim 1, 2, or 3, wherein the cells are maintained in a medium comprising a three-dimensional matrix, which produces the connexin43 protein.

2. An immortalized human pancreatic ductal cell line capable of producing insulin and expressing connexin43 gap junction protein derived by differentiation from normal human pancreatic duct epithelium gap junctional intracellular communication incompetent cells transfected with human papilloma virus genes E6 and E7 and available from Michigan State University, East Lansing, Mich. or the Department of Laboratory Medicine and Pathobiology, University Health Network, Toronto, Ontario, Canada.

5. A pluripotent human pancreatic ductal cell line immortalized with human papilloma virus genes E6 and E7 and which is capable of producing insulin, wherein the cells are (i) contact inhibited in complete keratinocyte serum-free medium containing growth factors, hormones and bovine pituitary extract (KSFM), (ii) capable of forming tubular/ductal structures in a medium comprising a three-dimensional matrix, (iii) gap junction intercellular communication competent in keratinocyte basal medium (KBM), and (iv) capable of expressing connexin 32 and 43 genes in KBM comprising c-AMP elevating agents.

6. The cell line of claim 5, wherein the human papilloma virus genes E6 and E7 are provided by a plasmid or a recombinant virus.

7. The cell line of claim 5, wherein the cell line is HPDE6c7 deposited as ATCC ______.

8. The cell line of claim 5, wherein the cell line is maintained as the pluripotent stem cell line in KSFM.

9. The cell line of claim 5, wherein the cell line is maintained as a differentiated cell line in a medium selected from the group consisting of KBM, KBM with C-AMP elevating agents, and a medium comprising a three-dimensional matrix.

10. The cell line of claim 5 or 9, wherein the c-AMP elevating agents are selected from the group consisting of 3-isobutyl-1-methylxanthine, forskolin, and mixture thereof.

11. A method for screening a chemical agent for determining an affect on cells which comprises:

(a) providing a human pancreatic ductal cell line immortalized with human papilloma virus genes E6 and E7 and which is capable of producing insulin, wherein the cells are gap junctional communication competent and are capable of expressing connexin43 gap junction protein upon induction by agents stimulating the production of cyclic AMP; and

(b) exposing the cell line to the chemical agent to screen the effect of the chemical agent on the cell line.

12. The method of claim 11, wherein the immortalized human pancreatic ductal cell line is derived by differentiation from normal human pancreatic duct epithelium gap junctional intracellular communication incompetent cells transfected with human papilloma virus genes E6 and E7 and available from Michigan State University, East Lansing, Mich. or the Department of Laboratory Medicine and Pathobiology, University Health Network, Toronto, Ontario, Canada.

13. The method of claim 11, wherein the human papillomavirus genes E6 and E7 are provided by a retrovirus.

14. The method of claim 11, 12, or 13, wherein the cells are maintained in a medium comprising a three-dimensional matrix, which produces the connexin43 protein.

15. The method of claim 11 or 12, wherein the chemical agent is tested on the cell line for an ability to cause the cell line to become tumorigenic.

16. The method of claim 11, wherein the chemical agent is tested on the cell line for an ability to affect the production of insulin.

18. The method of claim 17, wherein the human papillomavirus E6 and E7 genes are provided by a retrovirus.

19. The method of claim 17, wherein an immortalized human pancreatic ductal cell line is derived by differentiation from normal human pancreatic duct epithelium gap junctional intracellular communication incompetent cells transfected with human papilloma virus genes E6 and E7 and available from Michigan State University, East Lansing, Mich.

20. The method of claim 17, 18, or 19, wherein the cells are maintained in a medium comprising a three-dimensional matrix, which produces the connexin43 protein.

17. A method for differentiating cells which comprises:

(a) providing normal human pancreatic duct epithelium cells transfected with human papilloma virus genes E6 and E7, wherein the cells are gap junctional intracellular connection incompetent and are incapable of producing insulin and connexin43; and

(b) maintaining the cells of step (a) with a cyclic AMP elevating agent in basal medium, without hormones and growth factors, to produce the differentiated cells which are gap junctional intracellular connection competent and which produce connexin43 gap junction protein.

21. A method for determining the ability of a chemical agent to affect differentiation of insulin-producing cells or tissues, which comprises:

(a) providing a pluripotent human pancreatic ductal cell line immortalized with human papilloma virus genes E6 and E7 and which is capable of producing insulin, wherein the cells are (i) contact inhibited in complete keratinocyte serum-free medium containing growth factors, hormones and bovine pituitary extract (KSFM), (ii) capable of forming tubular/ductal structures in a medium comprising a three-dimensional matrix, (iii) gap junction intercellular communication competent in keratinocyte basal medium (KBM), and (iv) capable of expressing connexin 32 and 43 genes in KBM comprising c-AMP elevating agents;

(b) exposing the cell line to the chemical agent in complete medium or basal medium with or without c-AMP elevating agents; and

(c) determining the effect of the chemical agent on differentiation.

22. The method claim 21, wherein the human papilloma virus genes E6 and E7 are provided by a plasmid or a recombinant virus.

23. The method of claim 21, wherein the cell line is HPDE6c7 deposited as ATCC ______.

24. The method of claim 21, wherein the c-AMP elevating agents are selected from the group consisting of 3-isobutyl-1-methylxanthine, forskolin, and mixture thereof.

26. The method claim 25, wherein the human papilloma virus genes E6 and E7 are provided by a plasmid or a recombinant virus.

27. The method of claim 25, wherein the cell line is HPDE6c7 deposited as ATCC ______.

28. The method of claim 25, wherein the c-AMP elevating agents are selected from the group consisting of 3-isobutyl-1-methylxanthine, forskolin, and mixture thereof.

30. The method claim 29, wherein the human papilloma virus genes E6 and E7 are provided by a plasmid or a recombinant virus.

31. The method of claim 29, wherein the cell line is HPDE6c7 deposited as ATCC ______.

32. The cell line of claim 29, wherein the c-AMP elevating agents are selected from the group consisting of 3-isobutyl-1-methylxanthine, forskolin, and mixture thereof.

25. A method for determining the ability of a chemical agent to affect production of insulin, which comprises:

(a) providing a pluripotent human pancreatic ductal cell line immortalized with human papilloma virus genes E6 and E7 and which is capable of producing insulin, wherein the cells are (i) contact inhibited in complete keratinocyte serum-free medium containing growth factors, hormones and bovine pituitary extract (KSFM), (ii) capable of forming tubular/ductal structures in a medium comprising a three-dimensional matrix, (iii) gap junction intercellular communication competent in keratinocyte basal medium (KBM), and (iv) capable of expressing connexin 32 and 43 genes in KBM comprising c-AMP elevating agents;

(b) exposing the cell line to the chemical agent in complete medium or basal medium with or without c-AMP elevating agents; and

(c) determining the effect of the chemical agent on production of insulin.

29. A method for determining the ability of a chemical agent to induce malignant proliferation of insulin-producing cells or tissues, which comprises:

(a) providing a pluripotent human pancreatic ductal cell line immortalized with human papilloma virus genes E6 and E7 and which is capable of producing insulin, wherein the cells are (i) contact inhibited in complete keratinocyte serum-free medium containing growth factors, hormones and bovine pituitary extract (KSFM), (ii) capable of forming tubular/ductal structures in a medium comprising a three-dimensional matrix, (iii) gap junction intercellular communication competent in keratinocyte basal medium (KBM), and (iv) capable of expressing connexin 32 and 43 genes in KBM comprising c-AMP elevating agents;

(b) exposing the cell line to the chemical agent in complete medium or basal medium with or without c-AMP elevating agents; and

(c) determining whether the cells undergo malignant proliferation.

33. A method for treating type-I diabetes in a mammal comprising:

(a) providing a therapeutically effective amount of a human pancreatic ductal cell line immortalized with human papilloma virus genes E6 and E7 and which is capable of producing insulin, wherein the cells are gap junctional intercellular communication competent and are capable of expressing connexin43 gap junction protein upon induction by agents stimulating the production of cyclic AMP, positioned in a means for producing an artificial pancreas; and

(b) implanting the artificial pancreas in the mammal wherein the artificial pancreas produces insulin.

34. The method of claim 33, wherein the immortalized human pancreatic ductal cell line is derived by differentiation from normal human pancreatic duct epithelium gap junctional intracellular communication incompetent cells transfected with human papilloma virus genes E6 and E7 and available from Michigan State University, East Lansing, Mich.

35. The method of claim 33, wherein the artificial pancreas comprises the immortalized cell line positioned within a selectively permeable device which is connected to the vasculature of the mammal.

36. A human pancreatic ductal epithelial cell line wherein the cells of the cell line are immortalized with an agent selected from the group consisting of human papilloma virus (HPV) genes E6 and E7, SV40 T antigen, Rous sarcoma virus, one or more oncogenes selected from the group consisting of ras, scr, and neu, and a chemical mutagen selected from the group consisting of N-methyl-N-nitro-N-nitrosoguanidine (MNNG), methyl methane sulfonate(MMS), nitrosourea (NMU), dimethylbenz[a]anthracine (DBMA), 4-nitroquinoline-N-oxide (NQO), and nickel(II) and which is capable of producing insulin, wherein the cells are gap junctional intercellular communication competent and are capable of expressing connexin43 gap junction protein upon induction by agents stimulating the production of cyclic AMP.

37. A method for making an immortalized human pancreatic ductal epithelial cell line which is capable of producing insulin, wherein the cells are gap junctional intercellular communication competent and are capable of expressing connexin43 gap junction protein upon induction by agents stimulating the production of cyclic AMP, comprising:

(a) isolating ductal tissue from human pancreatic tissue;

(b) incubating the ductal tissue in a cell culture to form a monolayer of cells growing from the ductal tissue;

(c) treating the monolayer of cells with an agent selected from the group consisting of human papilloma virus (HPV) genes E6 and E7, SV40 T antigen, Rous sarcoma virus, one or more oncogenes selected from the group consisting of ras, scr, and neu, and a chemical mutagen selected from the group consisting of N-methyl-N-nitro-N-nitrosoguanidine (MNNG), methyl methane sulfonate(MMS), nitrosourea (NMU), dimethylbenz[a]anthracine (DBMA), 4-nitroquinoline-N-oxide (NQO), and nickel(II) for a time sufficient to immortalize the cells; and

(d) growing the immortalize cells for a time sufficient to allow the cells that are not immortalized to die to produce the immortalized cell line, wherein the immortalized cell line is capable of producing insulin, and wherein the immortalized cells of the cell line are gap junctional intercellular communication competent and are capable of expressing connexin43 gap junction protein upon induction by agents stimulating the production of cyclic AMP.